These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8093399)

  • 1. Propranolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia.
    Kajinami K; Takekoshi N; Mabuchi H
    Lancet; 1993 Jan; 341(8837):124-5. PubMed ID: 8093399
    [No Abstract]   [Full Text] [Related]  

  • 2. Probucol-induced QT prolongation and torsades de pointes.
    Matsuhashi H; Onodera S; Kawamura Y; Hasebe N; Kohmura C; Yamashita H; Tobise K
    Jpn J Med; 1989; 28(5):612-5. PubMed ID: 2585889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic ventricular tachycardia (Torsade de Pointes) associated with the use of probucol.
    Gohn DC; Simmons TW
    N Engl J Med; 1992 May; 326(21):1435-6. PubMed ID: 1569995
    [No Abstract]   [Full Text] [Related]  

  • 4. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review.
    Brandriss MW; Richardson WS; Barold SS
    Clin Infect Dis; 1994 Jun; 18(6):995-8. PubMed ID: 8086567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
    Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsades de pointes induced by concomitant use of chlorpheniramine and propranolol: An unusual presentation with no QT prolongation.
    Ösken A; Yelgeç NS; Zehir R; Öz TK; Yaylacı S; Akdemir R; Gündüz H
    Indian J Pharmacol; 2016; 48(4):462-465. PubMed ID: 27756965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced QT prolongation and sudden death.
    Del Rosario ME; Weachter R; Flaker GC
    Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probucol-induced QT prolongation and syncope.
    Tamura M; Ueki Y; Ohtsuka E; Oribe M; Seita M; Oribe K; Ito M
    Jpn Circ J; 1994 May; 58(5):374-7. PubMed ID: 8022053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provocative testing and drug response in a patient with the long QT syndrome.
    Kawade M; Ohe T; Kamiya T
    Br Heart J; 1995 Jul; 74(1):67-70. PubMed ID: 7662457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case.
    Wang MH; Tseng CD; Bair SY
    Hum Exp Toxicol; 1998 Oct; 17(10):587-90. PubMed ID: 9821023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
    Singh M; Arora R; Jawad E
    Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced QT prolongation: consequences and current dilemma.
    Dubrey SW; Grocott-Mason R
    Br J Hosp Med (Lond); 2007 Jan; 68(1):50-1. PubMed ID: 17260721
    [No Abstract]   [Full Text] [Related]  

  • 17. QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.
    Manini AF; Raspberry D; Hoffman RS; Nelson LS
    J Med Toxicol; 2007 Dec; 3(4):178-81. PubMed ID: 18072173
    [No Abstract]   [Full Text] [Related]  

  • 18. Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug.
    Husain Z; Hussain K; Nair R; Steinman R
    Cardiol J; 2010; 17(5):509-11. PubMed ID: 20865683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
    Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
    Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.